131172-64-0

Basic information

• Product Name: 1H-Indole-2-carboxylicacid,4,5,6,7-tetrahydro-(9CI)
• Synonyms: 1H-Indole-2-carboxylicacid,4,5,6,7-tetrahydro-(9CI);1H-Indole-2-carboxylic acid, 4,5,6,7-tetrahydro-
• CAS NO: 131172-64-0
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.191
• Product Categories: GLYCINESCAFFOLD
• Mol File: 131172-64-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indole-2-carboxylicacid,4,5,6,7-tetrahydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-2-carboxylicacid,4,5,6,7-tetrahydro-(9CI)(131172-64-0)
• EPA Substance Registry System: 1H-Indole-2-carboxylicacid,4,5,6,7-tetrahydro-(9CI)(131172-64-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 131172-64-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1H-Indole-2-carboxylic acid, 4,5,6,7-tetrahydro (9CI) is used as a building block in pharmaceutical research for the development of various drug molecules. Its unique structural features and properties contribute to the creation of novel compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-Indole-2-carboxylic acid, 4,5,6,7-tetrahydro (9CI) serves as a key intermediate for the synthesis of complex organic compounds. Its reactivity and versatility allow for the formation of a wide range of chemical products, expanding the scope of chemical research and development.
Used in Medicinal Chemistry:
1H-Indole-2-carboxylic acid, 4,5,6,7-tetrahydro (9CI) has potential applications in medicinal chemistry due to its structural features and properties. It can be incorporated into drug molecules to enhance their pharmacological properties, such as potency, selectivity, and bioavailability, leading to the discovery of new therapeutic agents.

Upstream product

• 131172-58-2 2,2,2-trifluoro-1-(4,5,6,7-tetrahydro-1H-indol-2-yl)ethanone 
• 65880-18-4 4,5,6,7-tetrahydro-1H-indole-2-carboxylic acid ethyl ester 
• 65541-69-7 4,5,6,7-tetrahydro-2-(trifluoroacetyl)-1-vinylindole 
• 822-87-7 2-Chlorocyclohexanone 
• 1477-50-5 Indole-2-carboxylic acid 

Downstream Products

• 685142-01-2 3-phenyl-2(RS)-{2-[(4,5,6,7-tetrahydro-1H-indole-2-carbonyl)-amino]-benzoylamino}-propionic acid ethyl ester 

Relevant articles and documents

Hexafluoroisopropanol: A powerful solvent for the hydrogenation of indole derivatives. Selective access to tetrahydroindoles or cis-fused octahydroindoles

Pd/C in HFIP was used to hydrogenate indole derivatives under relatively mild conditions, leading to potential synthetic intermediates of bioactive compounds. Depending on their substitution, tetrahydroindoles or octahydroindoles could selectively be obtained.

PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE

The present invention provides a compound which indicates a histamine H4 receptor modulating activity.A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R1 is substituted or unsubstituted alkyl, etc., W is -O-, etc., n is an integer of 0 to 6; X is N(R7)- or -O-; R7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is-C(R8)= or -N=; R8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is =O, =S, etc.; B ring is a ring represented by the following formula wherein R10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R11, R12a and R12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.The present invention provides a compound which indicates a histamine H4 receptor modulating activity. A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R 1 is substituted or unsubstituted alkyl, etc., W is -O-, etc., n is an integer of 0 to 6; X is N(R 7 )- or -O-; R 7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is-C(R 8 )= or -N=; R 8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is =O, =S, etc.; B ring is a ring represented by the following formula wherein R 10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R 11 , R 12a and R 12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.

Anthranilic acid based CCK1 antagonists: The 2-indole moiety may represent a "needle" according to the recent homonymous concept

Recently we described an innovative class of non-peptide CCK1 antagonists keeping appropriate pharmacophoric groups on the anthranilic acid employed as a molecular scaffold. The lead compound obtained, VL-0395, characterized by the presence of Phe and the 2-indole moiety at the C- and N-termini of anthranilic acid, respectively, is endowed with submicromolar affinity towards CCK1 receptors. Thus, we have prepared and tested on CCK receptors a library of VL-0395 analogues in order to investigate the precise topological and essential key interactions of the 2-indole group of the lead with the CCK1 receptor. The obtained results confirm that this group establishes very specific interactions with this receptor sub-site and may be viewed as a "needle" group.

SYNTHESIS OF PYRROLE-2-CARBOXYLIC ACIDS AND THEIR N-VINYL DERIVATIVES

Haloform cleavage of 2-trifluoroacetyl- and N-vinyl-2-trifluoroacetylpyrroles gives pyrrole-2-carboxylic acids and their N-vinyl derivatives in good yields; most of these compounds do not melt between 120-190 deg C, but rather decompose with CO2 evolution.